Jump to content

Pharmacovigilance Agreements: Guidance on the Quality Oversight and Operational Aspects eBooklet

Price: USD ($) 11.00

Please note: payment is required before the ebooklet is sent via email.  However if you need earlier access please contact publications@therqa.com.

VAT on Electronic Books is chargeable in the UK and EU. Please see the 'Booklet Terms and Conditions' for further details.

The purpose of this booklet is to provide some guidance on the quality oversight and operational aspects of PVAs for professionals working in PV, Legal, Regulatory Affairs and QA departments.

The booklet aims to provide you with:

•  An overview of the types of agreement
•  The items which you may need to consider when developing  and implementing PVAs 
•  The items to consider and to prioritise for QA oversight 
•  A matrix of the typical clauses according to your agreement type.



Types of agreements  

  • Co-development arrangements 
  • Co-Marketing and Licensing  
  • Distribution and Wholesaler Agreements 
  • Manufacturing arrangements 
  • Purchase agreements/tenders/charitable donations 
  • Service level agreements  
  • Business service providers for marketing related activities   
  • Service providers for delegated PV activities or PV supporting functions   
  • Collaboration arrangement with not-for-profit organisation
  • Operational aspects 

Quality oversight

  • PVA Compliance 
  • Point to consider when developing a quality oversight strategy  
  • Methods of quality oversight 
  • Questionaire assessment 
  • Conclusions 


Sandra Dunlavy, Astellas 
Magda Daudin, Janssen 
Andrew Cooper, GlaxoSmithKline 
Kieran O’Donnell, TMC Pharma Thomas Henn, United Therapeutics Europe Ltd 

Tomoko Yanai, Santen Pharmaceutical Co., Ltd 
Shigeo Suzuki, MSD K.K. Ayami Komatsu, Japan Tobacco INC. 
Teiki Iwaoka, CAC Croit Corporation 
Madoka Sasaki, Sumitomo Dainippon Pharma Co. Ltd. 


Virtual Event Platform